Acadia Pharmaceuticals Files Q1 2025 10-Q
Ticker: ACAD · Form: 10-Q · Filed: May 8, 2025 · CIK: 1070494
| Field | Detail |
|---|---|
| Company | Acadia Pharmaceuticals Inc (ACAD) |
| Form Type | 10-Q |
| Filed Date | May 8, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, pharmaceuticals, financials, quarterly-report
TL;DR
Acadia Pharma's Q1 2025 10-Q is in. Check financials.
AI Summary
Acadia Pharmaceuticals Inc. filed its 10-Q for the period ending March 31, 2025. The filing details their financial performance and business operations. Key financial data and operational aspects are presented within this report.
Why It Matters
This filing provides investors and analysts with the latest financial snapshot of Acadia Pharmaceuticals, crucial for understanding the company's current health and future prospects.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Acadia faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 2025-03-31 — Reporting Date (End of the first quarter of 2025)
- 2024-11-30 — Previous Fiscal Year End (Context for financial comparisons)
Key Players & Entities
- ACADIA PHARMACEUTICALS INC (company) — Filer
- 20250331 (date) — Period of Report
- 20250508 (date) — Filed as of Date
- Saniona (company) — License Agreement Partner
- Neuren Pharmaceuticals Limited (company) — License Agreement Partner
- DAYBUE (product) — Product Mentioned
- PRV (product) — Product Mentioned
FAQ
What is the reporting period for this 10-Q filing?
The Conformed Period of Report is 20250331, meaning the filing covers the period ending March 31, 2025.
Who are the key partners mentioned in relation to license agreements?
The filing mentions license agreements with Saniona and Neuren Pharmaceuticals Limited.
What products are referenced in the context of FDA approval and sales?
The filing references FDA Approval Sales of DAYBUE and Sale of PRV.
What is the company's Standard Industrial Classification?
The company's Standard Industrial Classification is Pharmaceutical Preparations [2834].
When was the corporate office space lease agreement entered into?
The corporate office space lease agreement was entered into on 2021-03-31.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 8, 2025 regarding ACADIA PHARMACEUTICALS INC (ACAD).